CA3244108A1 - METHODS FOR TREATING BLOOD DISORDERS WITH MONOSPACTIC ANTIBODY TARGETING VWF - Google Patents

METHODS FOR TREATING BLOOD DISORDERS WITH MONOSPACTIC ANTIBODY TARGETING VWF

Info

Publication number
CA3244108A1
CA3244108A1 CA3244108A CA3244108A CA3244108A1 CA 3244108 A1 CA3244108 A1 CA 3244108A1 CA 3244108 A CA3244108 A CA 3244108A CA 3244108 A CA3244108 A CA 3244108A CA 3244108 A1 CA3244108 A1 CA 3244108A1
Authority
CA
Canada
Prior art keywords
vwf
targeted
methods
blood disorders
treating blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3244108A
Other languages
English (en)
French (fr)
Inventor
Henrik Ostergaard
Prafull S GANDHI
Johan H. Faber
Catherine Rea
Benny Sorensen
Original Assignee
Hemab Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemab Aps filed Critical Hemab Aps
Publication of CA3244108A1 publication Critical patent/CA3244108A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3244108A 2022-02-15 2023-02-14 METHODS FOR TREATING BLOOD DISORDERS WITH MONOSPACTIC ANTIBODY TARGETING VWF Pending CA3244108A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263268040P 2022-02-15 2022-02-15
US63/268,040 2022-02-15
US202263269000P 2022-03-08 2022-03-08
US63/269,000 2022-03-08
PCT/EP2023/053681 WO2023156409A1 (en) 2022-02-15 2023-02-14 Methods of treating blood disorders with vwf-targeted monospecific antibodies

Publications (1)

Publication Number Publication Date
CA3244108A1 true CA3244108A1 (en) 2023-08-24

Family

ID=85278579

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3244108A Pending CA3244108A1 (en) 2022-02-15 2023-02-14 METHODS FOR TREATING BLOOD DISORDERS WITH MONOSPACTIC ANTIBODY TARGETING VWF

Country Status (8)

Country Link
US (1) US20250154283A1 (https=)
EP (1) EP4479435A1 (https=)
JP (1) JP2025507448A (https=)
KR (1) KR20240159860A (https=)
CN (1) CN119032109A (https=)
AU (1) AU2023221511A1 (https=)
CA (1) CA3244108A1 (https=)
WO (1) WO2023156409A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133583A1 (es) * 2023-08-16 2025-10-15 Hemab Aps Métodos para tratar trastornos de la sangre con anticuerpos monoespecíficos dirigidos a vwf
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides

Also Published As

Publication number Publication date
EP4479435A1 (en) 2024-12-25
JP2025507448A (ja) 2025-03-18
WO2023156409A1 (en) 2023-08-24
US20250154283A1 (en) 2025-05-15
KR20240159860A (ko) 2024-11-06
CN119032109A (zh) 2024-11-26
AU2023221511A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
WO2021097223A3 (en) Biparatopic cd73 antibodies
CA3244108A1 (en) METHODS FOR TREATING BLOOD DISORDERS WITH MONOSPACTIC ANTIBODY TARGETING VWF
EP4168454A4 (en) ANTIBODIES AND METHODS FOR THE TREATMENT OF CLAUDIN-ASSOCIATED DISEASES
EP4650367A3 (en) Anti-stem cell factor antibodies and methods of use thereof
IL316615A (en) Bispecific antibodies and methods for treating eye disease
EP4139364A4 (en) Bispecific antibodies for treating cd47-associated diseases
CA3260240A1 (en) FC HETERODIMER IL15/IL15R ALPHA FUSION PROTEIN COMBINATIONS AND FCRH5XCD3 BISPECIFIC ANTIBODIES FOR THE TREATMENT OF BLOOD CANCERS
WO2022197914A3 (en) Stem cell factor antibodies and methods of use thereof
CA3264922A1 (en) METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS RELATED TO ANGPTL3
CA3301362A1 (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
IL326550A (en) Methods for treating blood disorders using VWF-targeted monospecific antibodies
CA3280315A1 (en) Treatment of muscle related disorders with anti-human cacng1 antibodies
HK40104214A (en) Methods of treating red blood cell disorders
CA3261847A1 (en) CANCER TREATMENT METHODS USING ANTI-TIGIT ANTIBODIES
HK40090703A (en) Antibodies and methods for treating claudin-associated diseases
CA3291451A1 (en) Methods of treating cancer with anti-mica/b antibodies
CA3280941A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
HK40091622A (en) Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
HK40092097A (en) Cd38 antibodies for the treatment of human diseases
CA3273734A1 (en) Methods of treating cancer using anti-ddr1 antibodies
CA3283205A1 (en) Antibodies, antigen-binding fragments and methods of use
HK40079772A (en) Combination of bispecific fusion protein and anti-her2 antibody for tumor treatment
HK40098219A (en) Humanized anti-liv1 antibodies for the treatment of cancer
CA3278844A1 (en) Anti-cd38 antibodies for the treatment of autoimmune diseases
CA3270474A1 (en) Anti-bssl antibodies for the treatment of cancer

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240813

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240816

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240816

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20240912

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250207

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250211

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250429

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217